Vaxxis Bio: Signs licensing and distribution agreement with Nizhpharm for S-adenosylmethionine.

On February 3, MicroCore Bio announced that the company has signed a licensing and distribution agreement with Nizhny Novgorod Chemical Pharmaceutical Plant for the company's product Xidabenamine. According to the agreement, Nizhpharm will obtain exclusive rights for the research and development, registration, and commercialization of Xidabenamine in Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Mongolia, Russia, Tajikistan, Uzbekistan, Georgia, and Turkmenistan, as well as any future country regions with a capital located within the aforementioned territories that fall under its government jurisdiction. Nizhpharm will be responsible for the research and development, market registration, secondary packaging, transportation, and commercial sales of the product in the authorized regions. Nizhpharm will purchase the product from the company at the agreed price for commercial sales in the authorized area. Upon the effectiveness of the agreement, the company will receive a total of 10 million RMB as an upfront payment, regulatory material transfer milestones in the near future, and a total of 10 million RMB as local registration and listing milestones.